Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07593092 · ClinicalTrials.gov registry record · Phase 1
Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors
A Phase 1 study, sponsored by Xencor.
- Not yet
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT07593092: Clinical Trial Phase 1 study, sponsored by Xencor.
NCT07593092 is a Phase 1 study that has not yet begun recruiting, run by Xencor. The registered enrollment target is 90 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07593092, a Phase 1 study, has not yet begun recruiting, sponsored by Xencor.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine whether the investigational drug XmAb541 in combination with XmAb808 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 in combination with XmAb808 on tumor outcomes.
Interventions
- BIOLOGICAL XmAb541
- BIOLOGICAL XmAb808
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-06 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
What is known before NCT07593092 opens enrollment
NCT07593092 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% higher).
The record links to 0 conditions, and to 2 interventions - of which XmAb541 is the first listed.
NCT07593092 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07593092 about?
NCT07593092 is a clinical study titled "Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors". The primary purpose of this study is to determine whether the investigational drug XmAb541 in combination with XmAb808 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 in combination with XmAb808 on tumor o...
What is the current status of trial NCT07593092?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2026-06. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07593092?
The interventions under investigation include: XmAb541 (BIOLOGICAL), XmAb808 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07593092?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07593092's enrollment target sits among peer trials
90 628th of 2000 higher than 1,352 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia